Logo

Arcutis Reports Completion of Patient Enrollment for Roflumilast in P-III (STRATUM) Trial for the Treatment of Seborrheic Dermatitis

Share this
Arcutis Reports Completion of Patient Enrollment for Roflumilast in P-III (STRATUM) Trial for the Treatment of Seborrheic Dermatitis

Arcutis Reports Completion of Patient Enrollment for Roflumilast in P-III (STRATUM) Trial for the Treatment of Seborrheic Dermatitis

Shots:

  • The company has completed enrollment of the P-III (STRATUM) trial to evaluate the safety, tolerability, and efficacy of roflumilast (0.3% foam, qd) in 457 patients aged ≥9yrs. with moderate to severe seborrheic dermatitis
  • The 1EPs of the study is the proportion of patients who achieved an IGA score of “clear” or “almost clear” along with a 2-point improvement @8wks. The results are expected in mid-2022
  • The company is planning to submit an NDA in the US in H1’23. Roflumilast is a topical formulation of a highly potent and selective PDE4 inhibitor & has the potential to treat hair-bearing areas of the body including the face

Ref: Globe Newswire | Image: Arcutis

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions